New studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating promising effects in managing obesity and type second-type disease. Initial evidence suggest a unique process contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/